Supplementary Table 1. Serious Adverse Events Supplementary Table 2. Treatment-Related Serious Adverse Events Supplementary Table 3. Treatment-Related Adverse Events Occurring During the Dose-Limiting Toxicity Assessment Window Supplementary Table 4: All Adverse Events That Were Either Grade {greater than or equal to}3 or Occurred in >1 Patient Supplementary Figure 1A: This 57-year-old woman with anal cancer metastatic to liver and retroperitoneal and periportal nodes had progressive disease at enrollment. Restaging scans at 3 months showed a PR, which was confirmed at 4.5 months. Supplementary Figure 1B: CEA curve for patient with anal cancer with an ongoing durable confirmed PR. Supplementary Figure 1C: This 56-year-old woman with locally advanced cervical cancer s/p cisplatin/RT with metastases to lung within 3 months of initial treatment s/p topotecan/taxol plus bevacizumab was enrolled with enlarging right-sided lung masses. Restaging at 12 weeks showed a marked reduction in disease volume.